Official account of the Accelerating COVID-19 Therapeutic Interventions and Vaccines Acute Inpatient Anti-Thrombotic Study (ACTIV-4a)
Joined December 2020
- Tweets 28
- Following 26
- Followers 235
- Likes 72
Photos and videos
ACTIV4a retweeted
15 Nov 2021
>95% confidence in futility in non-critically #Covid_19 - @ACTIV4a still enrolling P2Y12 in critically ill patients - generating data at warp speed thanks to @NIHFunding @nih_nhlbi
15 Nov 2021
#AHA21 #LBCT
P2y12 Inhibitors in Noncritically Ill Hospitalized Pts With #Covid_19 #ACTIV4A
🩸thrombosis/inflam in #COVID
🩸RCT of P2Yy12, non-critical pt: 562 pts
🩸Stopped for futility; 40% women; Ticag used in 63%
🩸 No benefit of P2Yy12 in non-critical pts
@AHAMeetings
6
14
ACTIV4a retweeted
15 Nov 2021
#AHA21 #LBCT
P2y12 Inhibitors in Noncritically Ill Hospitalized Pts With #Covid_19 #ACTIV4A
🩸thrombosis/inflam in #COVID
🩸RCT of P2Yy12, non-critical pt: 562 pts
🩸Stopped for futility; 40% women; Ticag used in 63%
🩸 No benefit of P2Yy12 in non-critical pts
@AHAMeetings
1
5
24
ACTIV4a retweeted
8 Sep 2021
Superb @UofT_DoM Grand Rounds by @ecgoligher & @PatrickLawlerMD on the background, statistical approach & interpretation of the adaptive Bayesian design multiplatform @ATTACC_COVID / @ACTIV4a / @remap_cap anticoag in COVID trial.
nejm.org/doi/full/10.1056/NE…
nejm.org/doi/full/10.1056/NE…
4
13
In noncritically ill patients with #COVID19, anticoagulation increased the probability of survival to hospital discharge without organ support. nej.md/3jrrxJx #IDTwitter
3
115
227
ACTIV4a retweeted
4 Aug 2021
Great international collaboration @remap_cap @ATTACC_COVID @ACTIV4a
6
21
ACTIV4a retweeted
4 Aug 2021
The incredible efforts of so many have led to the publication of both #mpRCT papers reporting results of anticoagulation in #COVID19. @NEJM @ATTACC_COVID @remap_cap @ACTIV4a Most challenging/rewarding effort of my career nejm.org/doi/full/10.1056/NE… nejm.org/doi/full/10.1056/NE…
3
19
65
ACTIV4a retweeted
4 Aug 2021
Results of our therapeutic anticoagulation mpRCT with @ACTIV4a and @remap_cap is being live-streamed below.
Results have now been published in the @NEJM
Moderate state: bit.ly/3ioKptb
Critically ill: bit.ly/3lxzn7c
Editorial: bit.ly/3ltYnMj
1
31
62
ACTIV4a retweeted
3 Aug 2021
The final presentation timed with a public report. Come find out how the trial was done & what the role of therapeutic anticoagulation is in hospitalized patients with COVID-19. @ATTACC_COVID @remap_cap @ACTIV4a @UM_RadyFHS @UHN @CCCTG_ @canvector @ASH_hematology @JustinTrudeau
3 Aug 2021
Big night tomorrow night!
Free livestream from 20:30 UTC
criticalcarereviews.com
Supported by @MyIntensiveCare
17
42
ACTIV4a retweeted
3 Aug 2021
Big night tomorrow night!
Free livestream from 20:30 UTC
criticalcarereviews.com
Supported by @MyIntensiveCare
16
43
ACTIV4a retweeted
29 Jul 2021
Looking forward to discussing these results next week. This will impact COVID-19 practice worldwide 🌐
@ATTACC_COVID @remap_cap @ACTIV4a @charlot_summers @ecgoligher @PatrickLawlerMD
4
11
ACTIV4a retweeted
29 Jun 2021
For patients with #COVID19 receiving organ support in the ICU, #antiplatelet therapy with aspirin or P2Y12 inhibitor (which were found to be equivalent), was ineffective at improving death and organ support free days when compared to no #antiplatelet therapy. 1/8
2
69
154
ACTIV4a retweeted
17 May 2021
Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced use of organ support.
medrxiv.org/content/10.1101/…
5
70
141
ACTIV4a retweeted
24 Feb 2021
Just had our @ACTIV4a v1.1 protocol review - we hope to start randomizing to yes/no P2Y12i in hospitalized #COVID19 very soon!!@macky_neal @LucyKornblith @ATTACC_COVID @MaryCushmanMD @PatrickLawlerMD @statberry
1
2
35
ACTIV4a retweeted
In this free access @bmj_latest editorial we discuss
- the changing views & practice of thromboprophylaxis in hospitalised patients with COVI-19 through the pandemic
- the recent RCT interim evidence from @remap_cap @ATTACC_COVID & @ACTIV4a as to what is the best dose of LMWH
20 Feb 2021
Honoured to have co-written this @BMJ editorial dx.doi.org/10.1136/bmj.n487 @bhwords @PaulaErich MertDumantepe #thromboprophylaxs for #COVID19 important comment on current knowledge - all members of @thrombosisday steering group.
1
42
72
ACTIV4a retweeted
8 Feb 2021
Was nice discussing thrombosis and antithrombotic Rx in #covid19 from the mpRCT between @ACTIV4a @ATTACC_COVID @remap_cap
1
3
ACTIV4a retweeted
2 Feb 2021
A brief thread on interpreting organ support-free days as an endpoint for RCTs including @ATTACC_COVID @remap_cap @ACTIV4a
Visit the simulator linked here to explore how the endpoint is influenced by its various components
bit.ly/3oFZ57j
1
5
10
We are releasing the interim (final data coming and publication submission pending) data from our amazing mpRCT collaboration w/ @ATTACC_COVID @remap_cap to aid in clinician decision making on anticoagulants for #COVID19: nhlbi-connects.org/documents… @nih_nhlbi @macky_neal
1
15
37
ACTIV4a retweeted
25 Jan 2021
Early results of a worldwide trial, coordinated in part by researchers at Pitt, found that full doses of heparin, a blood thinner, were not only safe but also reduced the need for vital organ support, such as ventilation for COVID-19 patients.
More here: bit.ly/3oemMDy
15
32
ACTIV4a retweeted
23 Jan 2021
I’d say that the real forces of nature are @ACTIV4a @remap_cap @ATTACC_COVID and their tireless, dedicated, brilliant, amazing leadership. Grateful for the opportunity to learn from and work alongside all of you.
1
7
ACTIV4a retweeted
22 Jan 2021
Important announcement from ATTACC, @ACTIV4a and @remap_cap: Full-dose blood thinners decreased need for life support and improved outcomes in hospitalized COVID-19 patients news.umanitoba.ca/blood-thin…
12
122
217